News, Infos & good to know Forum: Community User: Lirumlarum1

Today NK posted position for “Associate Director - Manufacturing, Science and Technology

ImmunityBio Simulates SARS-CoV-2 Spike Protein Binding Using Molecular Dynamics Detailed computer modeling, completed in partnership with Microsoft, explains virulence of COVID-19 and provides key information that may lead to a better understanding of the multiple mutations currently occurring to the “spike” protein as the virus evolves https://ir.nantkwest.com/news-releases/news-release-details/immunitybio-simulates-sars-cov-2-spike-protein-binding-using?field_nir_news_date_value[min]=

The combined IBRX now has 108 job postings with 74 at NK and 34 at IB. A lot of them in mfg., supply chain, quality, and materials.

Timeline/Readouts/Phasenabschlüsse und Starts 2021 https://nantkwest.com/wp-content/uploads/2020/11/NantKwest-Corporate-Deck-v15-11-9-20lr.pdf

Einiges im Gange, was die Stellenausschreibungen angeht: (Linkedin) NantKwest = 158 employees/70 job openings. ImmunityBio= 207 employees/34 job openings. Combined: 365 employees/104 job openings. Both use WorkDay Applicant Tracking/HRIS system. Easy to merge.

Key Developments Jan-06-2021 Company Conference Presentations NantKwest, Inc. Presents at 10th Annual LifeSci Advisors Corporate Access Event, Jan-06-2021

Accomplished biotech executive and oncologist Dr. Fabio Benedetti joins ImmunityBio as Chief Strategy Officer. He’ll play a key role in the company’s commercialization strategy. https://mobile.twitter.com/immunitybio/status/1344340097022345219

Ohne den Punkt zwischen den o's

fo.ol.com

Here's a Cancer-Killing Stock to Buy for 2021 https://www.***.com/investing/2020/12/30/heres-a-cancer-killing-stock-to-buy-for-2021/

Kombinierte Pipeline von NantKwest und ImmunityBio: https://nantkwest.com/wp-content/uploads/2020/12/2020.12.21-NantKwest-ImmunityBio-FINAL.pdf

NEW YORK , Dec. 21, 2020 /PRNewswire/ -- WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of NantKwest, Inc. ("NantKwest" or the "Company") (NASDAQ: NK ) in connection with the Company's proposed merger with ImmunityBio, a privately-held late stage immunotherapy company.  Under the terms of the merger agreement, NantKwest will acquire ImmunityBio through a reverse merger pursuant to which, ImmunityBio shareholders will receive a fixed exchange ratio of 0.8190 shares of NantKwest for each share of ImmunityBio owned.  Upon completion of the transaction, NantKwest shareholders will own just 28% of the combined company, with ImmunityBio shareholders owning the majority of the newly-combined entity. WeissLaw is investigating whether NantKwest's board acted in the best interest of NantKwest's public shareholders in agreeing to the proposed transaction, whether the board was fully informed as to the valuation of ImunityBio, and whether all information regarding the process undertaken by the board and the valuation of the transaction will be fully and fairly disclosed to NantKwest public shareholders.  WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at  https://flashalert.me/?symbol=NK&source=PR&referer=https://stocktwits.com/&url=https://www.prnewswire.com:443/news-releases/shareholder-alert-weisslaw-llp-investigates-nantkwest-inc-301197170.html&s3=NK/2020-12-21/19-59-39_000000/pr/d2cd16de90fb949cec4c48e4cbfe9212/shareholder-alert-weisslaw-llp-investigates-nantkwest-inc-301197170.html

Why NantKwest Is Jumping Today A merger agreement with a fellow immunotherapy company is exciting investors today. What happened Shares of the cancer immunotherapy company NantKwest (NASDAQ:NK) are up by a healthy 36.6% as of 11:20 a.m. EST Monday morning. The biotech's shares are moving north today for two key reasons: Prior to the opening bell, NantKwest announced a stock-for-stock merger agreement with the privately held immunotherapy company ImmunityBio. Both companies are the brainchildren of billionaire surgeon Dr. Patrick Soon-Shiong. In a follow-up press release, ImmunityBio also announced that its IL-15 fusion protein known as Anktiva passed muster in a Phase II/III trial for patients with unresponsive non-muscle invasive bladder cancer. The drug reportedly produced a 72% complete response in this hard-to-treat indication after 12 months of treatment. So what Prior to this merger agreement, NantKwest's quest to become a leader in immuno-oncology through its natural killer cell therapy platform wasn't going quite as planned. The biotech's shares, in fact, were down by almost 60% since their initial public offering (IPO) last Friday, all thanks to a lack of substantial progress in the clinic. This much-needed merger agreement could breathe new life into NantKwest's long-term prospects, however, because this combined immunotherapy entity will end up sporting a whopping 13 clinical assets across both oncology and infectious diseases.   Now what The two companies reportedly expect the merger to close during the first half of 2021 -- pending shareholder approval by a majority of unaffiliated shareholders of NantKwest. Upon closing, the new company will retain the ImmunityBio name and trade on the Nasdaq stock exchange under the ticker IBRX.   Will this newly reworked biotech entity be a worthwhile growth stock? While a lot more info still needs to be unveiled before a buy, hold, or sell decision can be evaluated properly, this forthcoming company will have an impressively diverse immunotherapy pipeline. As such, it might be a good idea to keep a close watch on this developing story.